Alethea Capital Management LLC Buys Shares of 9,449 Eli Lilly and Company (LLY)
Alethea Capital Management LLC bought a new stake in shares of Eli Lilly and Company (NYSE:LLY) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 9,449 shares of the company’s stock, valued at approximately $808,000. Eli Lilly and accounts for approximately 0.9% of Alethea Capital Management LLC’s investment portfolio, making the stock its 29th largest holding.
A number of other institutional investors have also added to or reduced their stakes in the business. Advantus Capital Management Inc raised its position in shares of Eli Lilly and by 0.4% in the 1st quarter. Advantus Capital Management Inc now owns 97,698 shares of the company’s stock valued at $8,217,000 after acquiring an additional 425 shares during the period. Modera Wealth Management LLC bought a new position in shares of Eli Lilly and during the 1st quarter worth approximately $238,000. Partnervest Advisory Services LLC grew its stake in shares of Eli Lilly and by 12.4% during the 1st quarter. Partnervest Advisory Services LLC now owns 5,820 shares of the company’s stock worth $489,000 after acquiring an additional 643 shares in the last quarter. Stephens Inc. AR grew its stake in shares of Eli Lilly and by 4.5% during the 1st quarter. Stephens Inc. AR now owns 44,023 shares of the company’s stock worth $3,703,000 after acquiring an additional 1,901 shares in the last quarter. Finally, Bellevue Group AG grew its stake in shares of Eli Lilly and by 275.4% during the 1st quarter. Bellevue Group AG now owns 131,400 shares of the company’s stock worth $11,052,000 after acquiring an additional 96,400 shares in the last quarter. Institutional investors own 76.42% of the company’s stock.
In other Eli Lilly and news, SVP Jeffrey N. Simmons sold 12,500 shares of Eli Lilly and stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $86.46, for a total value of $1,080,750.00. Following the transaction, the senior vice president now owns 124,522 shares in the company, valued at $10,766,172.12. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of Eli Lilly and stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total value of $17,640,000.00. Following the completion of the transaction, the insider now owns 123,084,104 shares in the company, valued at approximately $10,856,017,972.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 651,088 shares of company stock worth $56,439,586. Company insiders own 0.20% of the company’s stock.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, beating the Zacks’ consensus estimate of $1.03 by $0.02. The business had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. Eli Lilly and’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.88 earnings per share. sell-side analysts expect that Eli Lilly and Company will post 4.21 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be given a $0.5625 dividend. This represents a $2.25 dividend on an annualized basis and a yield of 2.60%. The ex-dividend date of this dividend is Wednesday, February 14th. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s payout ratio is currently 98.58%.
Several brokerages have recently weighed in on LLY. Credit Suisse Group reaffirmed a “hold” rating on shares of Eli Lilly and in a research note on Wednesday. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the company a “sell” rating in a research note on Tuesday, December 5th. Jefferies Group reissued a “buy” rating and issued a $89.00 target price on shares of Eli Lilly and in a research note on Thursday, August 31st. Leerink Swann raised their target price on shares of Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a research note on Monday, October 23rd. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $105.00 target price (up from $103.00) on shares of Eli Lilly and in a research note on Friday, September 8th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $90.25.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Stock Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related stocks with our FREE daily email newsletter.